TMO Maintained by Barclays -- Price Target Raised to $775
Barclays maintained an 'Overweight' rating for Thermo Fisher Scientific (TMO) and raised its price target from $750 to $775. TMO's current price of $680.13 is 12.6% above its GF Value™ of $604.24, indicating potential overvaluation. The company has a GF Score™ of 84/100, showing strong performance but concerns in financial strength. Insider selling totaled $61.56M over the past three months.
How this was made
The 30-second read
Why it matters
The upgrade may attract short‑term buying, but valuation concerns and insider sell pressure could temper gains.
Market read
Analyst target raise is a modest catalyst for TMO, likely prompting limited buying interest.
What to watch
The stock appears overvalued at current price, with a trailing P/E above its 5‑year median.
Background
Barclays maintained an overweight rating and lifted its price target for Thermo Fisher Scientific, while GuruFocus data shows the stock trading above its intrinsic value and notable insider selling.
Ticker impact
Barclays raised its price target for Thermo Fisher Scientific to $775, indicating a bullish outlook.
likely upward pressure as investors price in the higher target
The new target is 3.3% above the previous level and follows an overweight rating, which typically prompts buying interest.
Market effects
May reinforce positive sentiment for the healthcare diagnostics sector.
Limited to US markets where TMO trades.
Low; impact confined to investors tracking large-cap biotech equipment firms.
Counterpoint
Insider selling of $61.5M could signal caution despite the target raise.
Key entities
- companyThermo Fisher Scientific
US‑listed provider of scientific instruments and services (ticker TMO).
- analystBarclays
Equity research firm issuing the rating and price target.
